The problem with glycopeptides

International Journal of Antimicrobial Agents

Volumn 30, Issue 1, 2007, Pages 1-3

  Gould, I M ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; GLYCOPEPTIDE; LINEZOLID; ORITAVANCIN; RIFAMPICIN; TEICOPLANIN; TELEVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CROSS RESISTANCE; DRUG COST; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERANCE; EDITORIAL; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PROTEIN BINDING; TISSUE DISTRIBUTION; TREATMENT FAILURE; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; EPIDEMIC; EUROPE; MORTALITY;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG TOLERANCE; GLYCOPEPTIDES; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 34249948464     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.03.006     Document Type: Editorial

References (36)

1. Hiramatsu K., Aritaka N., Hariaki N., et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350 (1997) 1670-1673
2. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., and Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40 (1997) 135-136
3. Sabath L.D., Wheeler N., Laverdiere M., Blazevic D., and Wilkinson B.J. A new type of penicillin resistance of Staphylococcus aureus. Lancet 1 (1977) 443-447
4. Gopal V., Bisno A.L., and Silverblatt F.J. Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations. JAMA 236 (1976) 1604-1606
5. Faville R.J., Zaske D.E., Kaplan E.L., Crossley K., Sabath L.D., and Quie P.G. Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin. JAMA 240 (1978) 1963-1965
6. Sorrell T.C., Packham D.R., Shanker S., Foldes M., and Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med 97 (1982) 344-350
7. Sievert D.M., Boulton M.L., Stoltman G., et al. Staphylococcus aureus resistant to vancomycin. MMWR Morb Mortal Wkly Rep 51 (2002) 565
8. Tenover F.C. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 48 (2004) 275-280
9. MacKenzie F.M., Greig P., Morrison D., Edwards G., and Gould I.M. Identification and characterisation of teicoplanin-intermediate Staphylococcus aureus blood culture isolates in NE Scotland. J Antimicrob Chemother 50 (2002) 689-697
10. Sancak B., Ercis S., Menemenlioglu D., Colakoglu S., and Hascelik G. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 56 (2005) 519-523
11. Kacica M., and McDonald L.C. Brief report: vancomycin resistant Staphylococcus aureus-New York, 2004. MMWR Morb Mortal Wkly Rep 53 (2004) 322-323
12. Garnier F., Chainier D., Walsh T., et al. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J Antimicrob Chemother 57 (2006) 146-149
13. Walsh T.R., Bolmstrom A., Quornstrom A., et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 39 (2001) 2439-2444
14. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering Jr. R.C., and Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42 (2004) 2398-2402
15. Howden B.P., Johnson P.D.R., Ward P.B., Stinear T.P., and Davies J.K. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50 (2006) 3039-3047
16. Wootton M., Walsh T.R., and MacGowan A.P. Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother 49 (2005) 3982-3983
17. Charles P.G.P., Ward P.B., Johnson P.D.R., Howden B.P., and Grayson M.L. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38 (2004) 448-451
18. Howden B.P., Ward P.B., Charles P.G.P., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38 (2004) 521-528
19. Moise-Broder P.A., Sakoulas G., Eliopoulos G.M., Schentag J.J., Forrest A., and Moellering R.C. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 38 (2004) 1700-1705
20. May J., Shannon K., King A., and French G. Glycopeptide tolerance in Staphylococcus aureus. J Antimicrob Chemother 42 (1998) 189-197
21. Koehl J.L., Muthaiyan A., Jayaswal R.K., Ehlert K., Labischinski H., and Wilkinson B.J. Cell wall composition and decreased autolytic activity and lysostaphin susceptibility and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 48 (2004) 3749-3757
22. Dykhuizen R.S., Harvey G., Stephenson N., Nathwani D., and Gould I.M. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother 39 (1995) 1842-1847
23. Gonzalez C., Rubio M., Romero-Vivas M., et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 29 (1999) 1171-1177
24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. M100-S16. Wayne, PA: CLSI; 2006.
25. Wang G., Hindler J.F., Ward K.W., and Bruckner D.A. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44 (2006) 3883-3886
26. Horváth A, Malmos G, Pesti N, Kristóf K, Nagy K, Rozgonyi F. Differences in antibiotic resistance between MRSA and MSSA strains isolated from hospitalized patients in Hungary. In: 8th European Congress of Chemotherapy, 25-28 October 2006, Budapest, Hungary. Hungarian Society of Chemotherapy; 2006 [abstract 98].
27. Horvath RL, Douglas J, Coulter C, Gribbles S. hVISA/VISA outbreak in a tertiary referral hospital. In: 8th European Congress of Chemotherapy, 25-28 October 2006, Budapest, Hungary. Hungarian Society of Chemotherapy; 2006 [abstract 99].
28. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., and Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med 166 (2006) 2138-2144
29. Kitzis M.D., and Goldstein F.W. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect 12 (2006) 81-95
30. Davey P.G., and Williams A.H. Teicoplanin monotherapy of serious infections caused by Gram-positive bacteria: a re-evaluation of patients with endocarditis or Staphylococcus aureus bacteraemia from a European open trial. J Antimicrob Chemother 27 (1991) 51-60
31. Lee-Such SC, Overholser BR, Munoz-Price LS. Nephrotoxicity associated with aggressive vancomycin therapy. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 27-30 September 2006, San Francisco, CA. Washington, DC, ASM Press; 2006 [abstract no. L-1298].
32. LaPlante K.L., and Rybak M.J. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48 (2004) 4665-4672
33. Benvenuto M., Benziger D.P., Yankelev S., and Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 50 (2006) 3245-3249
34. Charlesworth R., Warner M., Livermore D.M., and Wilson A.P.R. Comparison of four methods for detection of teicoplanin resistance in methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 58 (2006) 186-189
35. Wootton M. The need for accuracy in performing vancomycin intermediate resistant Staphylococcus aureus (VISA) and hetero-VISA detection methods. Int J Antimicrob Agents 28 (2006) 586
36. Wootton M., Howe R.A., Hillman R., Walsh T.R., Bennett P.M., and MacGowan A.P. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 47 (2001) 399-403